Objective: To develop a protocol for immunohistochemistry (IHC) to determine the Schlafen 11 (SLFN11) expression in formalin-fixed, paraffin-embedded (FFPE) high-grade serous ovarian carcinoma (HGSOC) samples. Study Design: We validated a reliable SLFN11 antibody (SLFN11-Ab) in IHC choosing between 2 antiSLFN11-Abs used for western blot through the development of a SLFN11-IHC protocol in culture cell block (CCB) of ovarian carcinoma and in an HGSOC tissue microarray (TMA) series. We applied our protocol to a case series of HGSOC samples to confirm our preliminary results. For each case we evaluated both the intensity score (IS) and the distribution score (DS). A final histological score (HS) was obtained as follows: HS=IS×DS. Results: In CCB and TMA series, the antibody #1 at 1:100 dilution was more reliable. This last one was used in our case series to confirm our IHC protocol. DS showed the following results: 27 cases were no stain, 11 cases showed staining for SLFN11 in <10% of cells, 16 cases showed staining in 10–40% of cells, and the remaining 15 cases showed stain in >40% of cells. IS showed the following results: 25 cases were no stain, in 19 cases a dominant weak stain, in 14 cases a moderate stain, and in 11 cases a strong stain. HS for SLFN11 expression presents a normal distribution with a prevalent (≈60%) intermediate expression. Conclusion: We develop a reproducible and standardized IHC protocol to determinate the SLFN11 expression in FFPE HGSOC samples using a modified western blot anti-SLFN11-Ab.

Schlafen 11 Assessment in High-Grade Serous Ovarian Carcinoma: Phenotypic and Histological Distribution

Domenico Ferraioli;Leonardo Peñuela;Simone Ferrero;Gabriella Cirmena;Alberto Ballestrero;Gabriele Zoppoli;Valerio Gaetano Vellone
2018-01-01

Abstract

Objective: To develop a protocol for immunohistochemistry (IHC) to determine the Schlafen 11 (SLFN11) expression in formalin-fixed, paraffin-embedded (FFPE) high-grade serous ovarian carcinoma (HGSOC) samples. Study Design: We validated a reliable SLFN11 antibody (SLFN11-Ab) in IHC choosing between 2 antiSLFN11-Abs used for western blot through the development of a SLFN11-IHC protocol in culture cell block (CCB) of ovarian carcinoma and in an HGSOC tissue microarray (TMA) series. We applied our protocol to a case series of HGSOC samples to confirm our preliminary results. For each case we evaluated both the intensity score (IS) and the distribution score (DS). A final histological score (HS) was obtained as follows: HS=IS×DS. Results: In CCB and TMA series, the antibody #1 at 1:100 dilution was more reliable. This last one was used in our case series to confirm our IHC protocol. DS showed the following results: 27 cases were no stain, 11 cases showed staining for SLFN11 in <10% of cells, 16 cases showed staining in 10–40% of cells, and the remaining 15 cases showed stain in >40% of cells. IS showed the following results: 25 cases were no stain, in 19 cases a dominant weak stain, in 14 cases a moderate stain, and in 11 cases a strong stain. HS for SLFN11 expression presents a normal distribution with a prevalent (≈60%) intermediate expression. Conclusion: We develop a reproducible and standardized IHC protocol to determinate the SLFN11 expression in FFPE HGSOC samples using a modified western blot anti-SLFN11-Ab.
File in questo prodotto:
File Dimensione Formato  
(2018) SFLN11 AQCH.pdf

accesso chiuso

Tipologia: Documento in Post-print
Dimensione 2.67 MB
Formato Adobe PDF
2.67 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11567/929313
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact